These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 30957954)
61. The histamine H Goncalves-Garcia M; Davies S; Savage DD; Hamilton DA Alcohol; 2024 Aug; 118():45-55. PubMed ID: 38705312 [TBL] [Abstract][Full Text] [Related]
68. Anticonvulsant effects of isomeric nonimidazole histamine H Sadek B; Saad A; Schwed JS; Weizel L; Walter M; Stark H Drug Des Devel Ther; 2016; 10():3633-3651. PubMed ID: 27853355 [TBL] [Abstract][Full Text] [Related]
69. Preliminary studies of 1,5-benzoxazepine derivatives as potential histamine H Stefaniak-Napieralska M; Walczyński K; Iwan M; Korga-Plewko A; Szałaj N; Więckowska A; Staszewski M Future Med Chem; 2024 Feb; 16(3):197-204. PubMed ID: 38189171 [No Abstract] [Full Text] [Related]
70. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives. Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963 [TBL] [Abstract][Full Text] [Related]
71. 1-[(2,3-Dihydro-1-benzofuran-2-yl) methyl]piperazines as novel anti-inflammatory compounds: Synthesis and evaluation on H Corrêa MF; Varela MT; Balbino AM; Torrecilhas AC; Landgraf RG; Troncone LRP; Fernandes JPDS Chem Biol Drug Des; 2017 Aug; 90(2):317-322. PubMed ID: 28109127 [TBL] [Abstract][Full Text] [Related]
72. Microinjection of histamine and its H Salimi S; Tamaddonfard E Eur J Pharmacol; 2019 Aug; 857():172450. PubMed ID: 31202805 [TBL] [Abstract][Full Text] [Related]
74. Development of a Conformational Histamine H Schihada H; Ma X; Zabel U; Vischer HF; Schulte G; Leurs R; Pockes S; Lohse MJ ACS Sens; 2020 Jun; 5(6):1734-1742. PubMed ID: 32397705 [TBL] [Abstract][Full Text] [Related]
75. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Leurs R; Bakker RA; Timmerman H; de Esch IJ Nat Rev Drug Discov; 2005 Feb; 4(2):107-20. PubMed ID: 15665857 [TBL] [Abstract][Full Text] [Related]
76. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995 [TBL] [Abstract][Full Text] [Related]
77. Histamine H3 and H4 receptors as novel drug targets. Tiligada E; Zampeli E; Sander K; Stark H Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107 [TBL] [Abstract][Full Text] [Related]
78. Histamine H3 receptor agonists. De Esch IJ; Belzar KJ Mini Rev Med Chem; 2004 Nov; 4(9):955-63. PubMed ID: 15544556 [TBL] [Abstract][Full Text] [Related]
79. New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present). Łażewska D; Kieć-Kononowicz K Expert Opin Ther Pat; 2014 Jan; 24(1):89-111. PubMed ID: 24131059 [TBL] [Abstract][Full Text] [Related]
80. Novel and highly potent histamine H3 receptor ligands. Part 3: an alcohol function to improve the pharmacokinetic profile. Labeeuw O; Levoin N; Poupardin-Olivier O; Calmels T; Ligneau X; Berrebi-Bertrand I; Robert P; Lecomte JM; Schwartz JC; Capet M Bioorg Med Chem Lett; 2013 May; 23(9):2548-54. PubMed ID: 23535326 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]